Hosted on MSN1mon
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASHVertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle cell disease or transfusion-dependent beta thalassemia. CASGEVY is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback